Safety profile and bleeding risk of ticagrelor compared with clopidogrel

Bibliography

• Yusuf S, Zhao F, Mehta SR, Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494-502
   PubMed Web of Science ®Google Scholar
• Sabatine MS, Cannon CP, Gibson CM, Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 2005;253:1179-89
   Web of Science ®Google Scholar
• Chen ZM, Jiang LX, Chen YP, Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 2005;366:1607-21
   PubMed Web of Science ®Google Scholar
• Steinhubl SR, Berger PB, Mann JT III, Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002;288:2411-20
   PubMed Web of Science ®Google Scholar
• Mehta SR, Yusuf S, Peters RJ, Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001;358:527-33
   PubMed Web of Science ®Google Scholar
• Savi P, Herbert JM. Clopidogrel and ticlopidine: P2Y12 adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis. Semin Thromb Hemost 2005;31(2):174-83
   PubMed Web of Science ®Google Scholar
• Husted S, van Giezen JJJ. Ticagrelor: the first reversibly binding oral P2Y12 receptor antagonist. Cardiovasc Ther 2009;27:259-74
   PubMed Web of Science ®Google Scholar
• Storey RF, Husted S, Harrington RA, Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes. J Am Coll Cardiol 2007;50:1852-6
   PubMed Web of Science ®Google Scholar
• Gurbel PA, Bliden KP, Butler K, Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation 2009;120:2577-85
   PubMed Web of Science ®Google Scholar
• Storey RF, Angiolillo DJ, Patil SB, Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy. J Am Coll Cardiol 2010;56:1456-62
   PubMed Web of Science ®Google Scholar
• Serebruany VL, Steinhubl SR, Berger RB, Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cariol 2005;45:246-51
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ, Fernandez-Ortiz A, Bernardo E. Variability in individual responsiveness to clopidogrel. J Am Coll Cardiol 2007;49:1505-16
   PubMed Web of Science ®Google Scholar
• Shuldiner AR, O'Connell JR, Bliden KP, Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 2009;302:849-57
   PubMed Web of Science ®Google Scholar
• Mega JL, Close SL, Wiviott SD, Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 2009;360:354-62
   PubMed Web of Science ®Google Scholar
• Gurbel PA, Bliden KP, Hiatt BL, Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 2003;107:2908-13
   PubMed Web of Science ®Google Scholar
• Cuisset T, Frere C, Quilici J, High post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome. J Thromb Haemost 2006;4:542-9
   PubMed Web of Science ®Google Scholar
• Bonello L, Tantry US, Marcucci R, Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol 2010;56:919-33
   PubMed Web of Science ®Google Scholar
• Matetzky S, Shenkman B, Guetta V, Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 2004;109:3171-5
   PubMed Web of Science ®Google Scholar
• Bliden KP, Tantry US, Storey RF, The effect of ticagrelor versus clopidogrel on high on-treatment platelet reactivity: combined analysis of the ONSET/OFFSET and RESPOND studies. Am Heart J 2011;162:160-5
   PubMed Web of Science ®Google Scholar
• Gurbel PA, Bliden KP, Butler K, Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study. Circulation 2009;121:1188-99
   Web of Science ®Google Scholar
• Wallentin L, Becker RC, Budaj A, Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361:1045-57
   PubMed Web of Science ®Google Scholar
• Chesebro JH, Knatterud G, Roberts R, Thrombolysis in myocardial infarction (TIMI) trial, Phase I: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase. clinical findings through hospital discharge. Circulation 1987;76:142-54
   PubMed Web of Science ®Google Scholar
• Husted S, Emanuelsson H, Heptinstall S, Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur Heart J 2006;27:1038-47
   PubMed Web of Science ®Google Scholar
• Cannon CP, Husted S, Harrington RA, Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial. J Am Coll Cardiol 2007;50:1844-51
   PubMed Web of Science ®Google Scholar
• Becker RC, Bassand JP, Budaj A, Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial. Eur Heart J 2011;32:2933-44
   PubMed Web of Science ®Google Scholar
• James S, Budaj A, Aylward P, Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function. Circulation 2010;122:1056-67
   PubMed Web of Science ®Google Scholar
• James SK, Roe MT, Cannon CP, Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomised PLATelet inhibition and patient Outcomes (PLATO) trial. BMJ 2011;342:d3527
   PubMed Web of Science ®Google Scholar
• Cannon CP, Harrington RA, James S, Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study. Lancet 2010;375:283-93
   PubMed Web of Science ®Google Scholar
• Held C, Asenblad N, Bassand JP, Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trial. J Am Coll Caridol 2011;57:672-84
   PubMed Web of Science ®Google Scholar
• Storey RF, Bilden KP, Patil SB, Incidence of dyspnea and assessment of cardiac and pulmonary function in patients with stable coronary artery disease receiving ticagrelor, clopidogrel, or placebo in the ONSET/OFFSET study. J Am Coll Cardiol 2010;56:185-93
   PubMed Web of Science ®Google Scholar
• Storey RF, Becker RC, Harrington RA, Characterization of dyspnoea in PLATO study patients treated with ticagrelor or clopidogrel and its association with clinical outcomes. Eur Heart J 2011;32:2945-53
   PubMed Web of Science ®Google Scholar
• Storey RF, Becker RC, Harrington RA, Pulmonary function in patients with acute coronary syndrome treated with ticagrelor or clopidogrel (from the Platelet Inhibition and Patient Outcomes [PLATO] pulmonary function substudy). Am J Cardiol 2011;108:1542-6
   PubMed Web of Science ®Google Scholar
• Ohman J, Kudira R, Albinsson S, el al. Ticagrelor induces adenosine triphosphate release from human red blood cells. Biochem Biophys Res Commun 2012;418:754-8
   PubMed Web of Science ®Google Scholar
• Burki NK, Dale WJ, Lee LY. Intravenous adenosine and dyspnea in humans. J Appl Physiol 2005;98:180-5
   PubMed Web of Science ®Google Scholar
• Scirica BM, Cannon CP, Emanuelsson H, The incidence of bradyarrhythmias and clinical bradyarrhythmic events in patients with acute coronary syndromes treated with ticagrelor or clopidogrel in the PLATO (Platelet Inhibition and Patient Outcomes) trial: results of the continuous electrocardiographic assessment substudy. J Am Coll Cardiol 2011;57:1908-16
   PubMed Web of Science ®Google Scholar
• Camm AJ, Garratt CJ. Adenosine and supraventricular tachycardia. NEJM 1991;325:1621-9
   PubMed Web of Science ®Google Scholar
• Mahaffey KW, Wojdyla DM. Carroll K, el al. Ticagrelor Compared With Clopidogrel by Geographic Region in the Platelet Inhibition and Patient Outcomes (PLATO) Trial. Circulation 2011;124:544-5
   PubMed Web of Science ®Google Scholar
• Ross AM, Gibbons RJ, Stone GW, A randomized, double-blinded, placebo-controlled multicenter trial of adenosine as an adjunct to reperfusion in the treatment of acute myocardial infarction (AMISTAD-II). J Am Coll Cardiol 2005;45:1775-80
   PubMed Web of Science ®Google Scholar
• Kloner RA, Forman MB, Gibbons RJ, Impact of time to therapy and reperfusion modality on the efficacy of adenosine in acute myocardial infarction: the AMISTAD-2 trial. Eur Heart J 2006;27:2400-5
   PubMed Web of Science ®Google Scholar
• The GUSTO investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993;329:673-82
   PubMed Web of Science ®Google Scholar